January 1, 2010Thrombosis and Haemostasis
Effect of two doses of aspirin on thromboxane biosynthesis and platelet function in patients undergoing coronary surgery
Key result
Early after CABG, 325 mg daily aspirin reduced the incidence of residual platelet activity compared to 100 mg daily.
Why the study?
Does aspirin 325 mg daily improve platelet inhibition and reduce thromboxane biosynthesis compared to 100 mg daily in patients early after CABG?
Population
56 patients undergoing coronary artery bypass graft (CABG)
Comparison
Aspirin 325 mg daily for five days vs Aspirin 100 mg daily for five days
Design
RCT, randomly assigned
Follow-up
5 days
Authors
Discussion
Loading...
Member takes
Implication
Supports 325 mg aspirin early post-CABG; extends RCT evidence on optimal dosing for platelet inhibition.
Study Design
Type
RCT (n=56)
Randomization
randomly assigned
Multicenter
No
Structured PICO
Does aspirin 325 mg daily improve platelet inhibition and reduce thromboxane biosynthesis compared to 100 mg daily in patients early after CABG?
P
Population
56 patients undergoing coronary artery bypass graft (CABG) treated for five days.
I
Intervention
Aspirin 325 mg daily (enteric coated formulation) for five days
C
Comparator
Aspirin 100 mg daily (enteric coated formulation) for five days
O
Outcome
Platelet function (measured by light-transmission aggregometry and point-of-care PFA-100) and thromboxane (TX) biosynthesis (in collagen-stimulated platelets, serum, urine, and LPS-cultured whole blood)surrogate
A higher dose of aspirin (325 mg daily) provides more effective thromboxane inhibition and reduces residual platelet activity compared to 100 mg daily early after CABG.
Cite This Study
Brambilla et al. (2010) conducted an RCT in Coronary artery bypass graft (CABG) (n=56). Aspirin vs. 100 mg daily was evaluated on Platelet function and thromboxane biosynthesis. Early after CABG, 325 mg daily aspirin reduced the incidence of residual platelet activity compared to 100 mg daily.